© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
Anticoagulants
Bleeding Improved with Apixaban versus VKA
April 22, 2019
Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.
Kidney Disease Patients May Not Be Getting OACs
April 22, 2019
Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.
Patients with Cognitive Impairment Less Likely to Get OACs
March 15, 2019
Study finds different anticoagulation treatment levels for patients with cognitive problems.
Two Studies Show Efficacy of Rivaroxaban, Other NOACs in Preventing Stroke
March 15, 2019
A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.
Increased Risk of Blood Clots and Death Seen with Higher Dose Tofacitinib
February 26, 2019
Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.
Cablivi for Acquired Thrombotic Thrombocytopenic purpura
February 18, 2019
What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.
Study: DOACs Equal to or Better Than Warfarin
February 16, 2019
DOACs are as good as warfarin in preventing atrial fibrillation complications.
New Guidelines: NOACs Preferred Over Warfarin in AFib
February 16, 2019
Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.
Racial Disparities Found in Oral Anticoagulant Prescription Patterns
January 14, 2019
Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.
Choice of Anticoagulant and Cotherapy with a PPI Affect Gastrointestinal Bleeding Risk
January 11, 2019
The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.